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Rationale: Controversy exists about the safety of long acting beta2-agonist (LABA) treatment,
in particular in children. Combination therapy with a LABA and an inhaled corticosteroid (ICS)
is prescribed to children with moderate asthma and can be stepped down by withdrawal of the
LABA when asthma is well controlled.
Objective: To analyze the effect of stepping down from LABA/ICS combination therapy
to monotherapy with the same dose of ICS on the airway response to mannitol in asthmatic
children.
Methods: 17 children, aged 12e17 years, with clinically stable asthma, receiving combination
therapy, were analyzed in this observational prospective open-label study. Children performed
a mannitol challenge at baseline and 30 4 days after their medication was stepped down to
ICS monotherapy. The changes in the provoking dose of mannitol to cause a 15% fall in FEV1
(PD15), response-dose ratio and recovery time following a short acting beta2-agonist to
95% of baseline FEV1 were assessed.
Results: Mannitol PD15 and response-dose ratio did not significantly change after stepping
down. The recovery time following a short acting beta2-agonist to 95% of baseline FEV1
was significantly shorter (pZ 0.01) after the withdrawal of the LABA.al; FeNO, Fraction of exhaled Nitric Oxide; FEV1, Forced Expiratory Volume in 1 s; ICS, Inhaled
a2-Agonist; PD15, Provoking Dose to cause a 15% fall in FEV1; SABA, Short Acting Beta2-Agonist; SD,
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692 E.T.G. Kersten et al.Conclusions: In short-term follow-up, stepping down clinically stable asthmatic children from
combination therapy to monotherapy with an ICS does not change airway hyperresponsiveness
(AHR) to mannitol but does shorten recovery time to baseline lung function following a rescue
short acting beta2-agonist.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Clinical guidelines recommend to step up asthma therapy
whenasthma is notwell controlled on a low tomoderate dose
of inhaled corticosteroids (ICS).1,2 In adults the addition of
a long acting beta2-agonist (LABA) leads to better asthma
control than increasing the dose of ICS.3 In children however,
combination therapy did not lead to a significant reduction,
but rather a trend towards an increased risk of asthma
exacerbations and hospital admissions.3 These trends raised
concern about the safety of combination therapy in children
and questions on whether and when the LABA should be
withdrawn when stepping down from combination therapy.
The suggested step down approach by current guidelines for
asthmatic adults is to reduce the ICS to the lowest dose
possible, while continuing the LABA.1,2 An alternative
approach, that was recently suggested by the US Food and
Drug Administration, is to discontinue the LABA once asthma
control is achieved and continue the ICS at the same dose.4
In a recent study in asthmatic adults by Reddel et al.,
both step down approaches were compared, and found
to result in no significant difference in FEV1, rescue bron-
chodilator use, methacholine PD20, sputum eosinophils
and FeNO.5 However, moderate exacerbations were less
frequent and subjects could be titrated to a lower dose of
ICS in subjects with combination therapy.5 Previous studies
in asthmatic adults comparing both step down approaches
found a deterioration of morning peak expiratory flow, dai-
ly symptoms and bronchodilator use in subjects who’s LABA
was withdrawn.6e8 The effect of withdrawal of the LABA
from combination therapy on airway hyperresponsiveness
(AHR) in children has not been extensively studied.
Regular use of short acting beta2-agonists (SABAs) and
LABAs leads to downregulation and desensitization of
the beta2-adrenoreceptor,9 which affects AHR in several
ways. Firstly, it results in a reduced bronchodilator effect
of rescue SABA treatment in circumstances of acute bron-
choconstriction: bronchodilator tolerance. Bronchodilator
tolerance develops after a single dose of a LABA and
reaches a maximum after 1 week of regular treatment.10 It
leads to a prolonged recovery time after bronchocon-
striction and the need for extra doses of rescue medi-
cation.10e14 Simultaneously, regular use of LABAs leads to
a reduced protection against AHR provoked by natural or
administered stimuli, such as methacholine,15,16 allergen16
and exercise.17 This is called bronchoprotective tolerance.
Furthermore, Hancox et al. have shown that regular use of
SABAs can even enhance AHR to exercise.12
In this study, we analyzed the effect of stepping down
clinically stable asthmatic children from LABA/ICS combi-
nation therapy to ICS monotherapy on AHR to mannitol.
Our hypothesis was that the withdrawal of the LABA would
lead to a decrease in AHR to mannitol.Methods
Subjects
Children with mild to moderate asthma, treated with LABA/
ICS combination therapy, who underwent a medication
reduction according to treatment guidelines,1,2 were
screened. Twenty four children with mild to moderate,
clinically stable asthma for >3 months (i.e. no hospital
admissions or use of systemic corticosteroids), aged 12e17
years, were asked to participate in this study. The study
was approved by the Medical Ethics Committee, Enschede.
All children and parents gave written informed consent.
Study design
This was an observational, prospective open-label study.
Children and their parents were contacted four and two
weeks prior to the first visit to emphasize on the impor-
tance of medication adherence. During the first visit to the
outpatient clinic, all children were interviewed about
medication use and adherence by the lung function assis-
tant. They performed a set of tests, including a mannitol
challenge, measurement of Fraction of exhaled Nitric
Oxide (FeNO) and an asthma control test. After the first
visit treatment was stepped down to ICS monotherapy. The
second visit was scheduled 30 4 days after the first visit.
During the second visit the same set of tests was per-
formed. Primary outcome was change in the provoking dose
of mannitol required to cause a 15% fall in FEV1 (PD15).
Secondary outcomes were changes in mannitol response-
dose ratio, recovery time to 95% of baseline FEV1
following a rescue SABA, FeNO and scores on the asthma
control test.
Spirometry
A MicroLoop MK8 Spirometer (Micromedical, Quayside,
United Kingdom) was used to measure pulmonary volumes
and flow-volume loops. All spirometric measurements were
performed in duplicate using a standard protocol.18
Mannitol challenge
The mannitol challenge was performed according to the
standard laboratory protocol, using the commercially
available mannitol test kit (Aridol, Pharmaxis, Frenchs
Forest, Sydney, Australia).19 Children were required to
withhold the use of leukotriene antagonists, intranasal
steroids, LABAs and ICSs for 24 h and SABAs for 8 h before
both mannitol challenges. No vigorous exercise was
permitted for 8 h before a mannitol challenge.
Stepping down combination therapy 693Thedoseprotocol consistedof 0, 5, 10, 20, 40, 80, 160, 160
and 160 mg mannitol. Children were asked to exhale
completely before taking a calm deep inspiration from the
device and subsequently hold their breath for 5 s. Children
were asked to exhale through their mouth to minimize
deposition in the nasopharynx. FEV1 was measured 60 s after
each dose of mannitol. The challenge ended when a 15%
fall in FEV1 frombaseline or a 10% fall between subsequent
doses occurred, or the cumulative dose of 635 mg mannitol
had been administered. Mannitol PD15 was calculated by
linear interpolation. The response-dose ratio was calculated
by taking the final percent fall in FEV1 recorded and dividing
it by the cumulative dose of mannitol administered.
After the challenge, children received a dose of 100 mg Sal-
butamolandFEV1wasmeasuredat tZ 1,3,5,10,15and20 min
until lung function had returned to 95% of baseline FEV1.
If FEV1 had not recovered to 95% of baseline after 10 min,
children received a second dose of 100 mg Salbutamol.
Fraction of exhaled nitric oxide
The single-breath online measurement method was used to
measure FeNO before any forced expiratory maneuvers.20
Children were asked to exhale to residual volume and
then inhale NO-free air through a hand-held nitric oxide
analyzer (Niox Mino, Aerocrine, Stockholm, Sweden).
Children inhaled near to total lung capacity and immedi-
ately exhaled at a constant flow rate of 50 ml/s. FeNO was
measured in the expired air by its reaction with ozone,
which is detected by chemiluminescence.
Asthma control test
The asthma control test is a 5 item survey assessing asth-
ma symptoms (daytime and nocturnal), use of rescueTable 1 Baseline characteristics of research population (NZ 1
Gender Age Med Daily dose ICS (mg) LTRA
1 M 11 FP/SAL 200 
2 M 13 BUD/F 400 þ
3 M 14 FP/SAL 100 
4 M 13 FP/SAL 250 
5 V 13 BUD/F 200 þ
6 V 12 BUD/F 400 
7 M 12 BUD/F 200 
8 V 14 FP/SAL 250 
9 M 14 FP/SAL 200 
10 V 13 FP/SAL 200 
11 M 13 BUD/F 200 þ
12 V 13 FP/SAL 500 
13 M 17 BUD/F 400 
14 M 13 FP/SAL 200 þ
15 M 13 BUD/F 400 
16 M 13 FP/SAL 200 
17 V 15 FP/SAL 200 þ
BUD/FZ budesonide/formoterol; FEV1Z forced expiratory volume in
corticosteroid; LABAZ long acting beta2-agonist; LTRAZ leukotriene
FEV1.medications and the effect of asthma on daily functioning.
Each item includes 5 response options corresponding to
a 5-point scale. The total score ranges from 5 points
(uncontrolled asthma) to 25 points (well controlled
asthma).
Statistical analysis
Statistical analysis was performed with SPSS Statistics
version 17.0 for Windows. Best values of spirometric
measurements of FEV1 were used for statistical calcula-
tions. Geometric means 95% confidence intervals (CI) of
mannitol PD15 and response-dose ratio were calculated
using the log-transformed values. Recovery time was
expressed as mean time to reach FEV1 95% of baseline.
Recovery curves were analyzed as the total area under the
curve. FeNO values were analyzed before and after natural
log transformation. Within group changes were analyzed
with a paired t-test or Wilcoxon-signed rank sum test, as
appropriate. Spearman’s rank correlation coefficient was
calculated for the correlations between FeNO, scores on the
asthma control test, FEV1, PD15 and response-dose ratio.
The difference between the number of children positive on
both mannitol challenges was analyzed with a McNemar
test. Statistical significance was defined as p< 0.05.
Results
Subjects
Twenty children were included, 17 of which completed the
study. In 3 children, the first mannitol challenge was
terminated before they reached a 15% fall in FEV1. One
subject was excluded because she was unable to perform
reproducible expiratory flow-volume curves. One subject7).
Baseline FEV1 (% pred.) PD15 mannitol (mg)
ICS/LABA ICS ICS/LABA ICS
104 98 >635 268
75 80 144 217
85 89 >635 >635
94 101 145 419
96 83 114 36
100 100 139 169
78 73 150 291
96 86 >635 256
104 81 132 66
68 82 49 115
84 91 236 241
98 108 308 467
69 61 255 58
101 97 >635 >635
76 91 250 221
120 122 367 409
117 120 >635 >635
1 s; FP/SALZ fluticasone propionate/salmeterol; ICSZ inhaled
receptor antagonist; PD15Z provoking dose to cause a 15% fall in
Table 2 Changes in outcome parameters.
LABA/ICS combination therapy ICS monotherapy p-value
FEV1 (% pred.) 92.1 15.6 91.9 15.7 0.96
PD15 (mg) 168.9 (56.9, 501.9) 183.7 (38.2, 884.9) 0.91
RDR (% fall in FEV1/mg) 0.05 (0.01, 0.36) 0.06 (0.01, 0.54) 0.81
Asthma control test 20.2 4.7 20.8 4.7 0.10
FeNO (ppb) 35.5 27.6 36.6 26.5 0.39
Recovery time to 95% of baseline FEV1 (min) 9.9 6.2 5.7 4.3 0.01
Area under the curve (%min) 1908.9 66.5 1944.2 51.4 0.04
Data expressed as mean  standard deviation (SD) or Geometric mean (95% CI). FeNOZ fraction of exhaled nitric oxide; FEV1Z forced
expiratory volume in 1 s; ICSZ inhaled corticosteroid; LABAZ long acting beta2-agonist; PD15Z provoking dose to cause a 15% fall in
FEV1; RDRZ Response-Dose Ratio.
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dose step, which interfered with the fixed time schedule
and one subject was unwilling to continue after the 8th
dose step because she didn’t like the taste of mannitol.
Patient characteristics are presented in Table 1.
Before the first mannitol challenge children reported an
average use of 1.8 puffs of SABAs per week (including pre-
exercise use) and a mean medication adherence of 81 15%
during the past 4 weeks. After the medication reduction
children reported an average use of 1.6 puffs of SABAs
per week and an adherence of 82 12%. Changes in all
outcome parameters are shown in Table 2.
Spirometry
Baseline FEV1 before the first mannitol challenge had
a normal distribution with a mean (SD) of 92.1 15.6%
predicted value, which was not significantly different from
baseline FEV1 before the second challenge (91.9 15.7%
predicted value, pZ 0.96).Figure 1 Individual changes in Mannitol PD15 (mg) after
regular treatment with LABA/ICS combination therapy and 4
weeks after stepping down to ICS monotherapy. ICSZ inhaled
corticosteroid; LABAZ long acting beta2-agonist; PD15Z pro-
voking dose to cause a 15% fall in FEV1.Mannitol challenge
Twelve children (70.6%) were positive on the first mannitol
challenge, defined by a fall in FEV1 15% after a cumula-
tive dose of635 mg mannitol. Fourteen children (82.4%)
were positive on the second challenge. The number of
children positive on a mannitol challenge was not signifi-
cantly different between both tests (pZ 0.50). Geometric
mean for the PD15 for children positive on the first chal-
lenge was 168.9 mg (95% CI: 56.9e501.9) and for the
second challenge 183.7 mg (95% CI: 38.2e884.9), which was
not significantly different (pZ 0.91; Fig. 1).
Mean maximum percent fall in FEV1 (SD) after the
first challenge was 15.6 5.4% after a mean cumulative
dose (SD) of 347 215 mg mannitol. After the second
challenge FEV1 fell 15.6 4.6% after a cumulative dose of
331 196 mg. Geometric mean of the response-dose ratio
did not change after the medication reduction (pZ 0.81).
Children using leukotriene antagonists did not have
a different response to mannitol than children not using
these medications.
Recovery
Mean [Range] recovery time following a SABA was 9.9 min
[1e20] after the first mannitol challenge and 5.7 min
[0e15] after the second challenge, which was significantly
shorter (pZ 0.01; Fig. 2). Six children needed a second
dose of 100 mg Salbutamol after the first challenge and only
one child after the second challenge. Recovery time after
mannitol was not age dependent. The total area under the
recovery curve (SD) was also significantly larger after the
second challenge (1908.9 66.5%min vs. 1944.2 51.4%
min, pZ 0.04).
Fraction of exhaled nitric oxide
There was no significant difference in FeNO measured
before both challenges (35.5 27.6 vs. 36.6 26.5 ppb;
pZ 0.39; Fig. 3). There was no correlation between FeNO
and mannitol PD15 or response-dose ratio.
Asthma control test
There was no significant difference between symptom
scores on the asthma control test after the medication
Figure 2 Percentage of patients with FEV1 recovered to
95% of baseline after 100 mg Salbutamol at resp. 0 and 10 min
after a mannitol challenge. ICSZ inhaled corticosteroid; LAB-
AZ long acting beta2-agonist.
Stepping down combination therapy 695reduction (20.2 4.7 vs. 20.8 4.7 points, pZ 0.10).
There was no correlation between scores on the asthma
control test and baseline FEV1, FeNO, mannitol PD15 and
response-dose ratio.
Discussion
In this study, we monitored stepping down from LABA/ICS
combination therapy to ICS monotherapy in clinically stable
asthmatic children. The withdrawal of the LABA did not
change baseline FEV1, ACT score, FeNO or SABA use. ThereFigure 3 Individual changes in Fraction of exhaled Nitric
Oxide (ppb) after regular treatment with LABA/ICS combina-
tion therapy and 4 weeks after stepping down to ICS mono-
therapy. ICSZ inhaled corticosteroid; LABAZ long acting
beta2-agonist.was no difference in Mannitol PD15 and response-dose ratio.
However, with LABA/ICS combination therapy there was a
delayed recovery after the administration of a SABA and
more children needed a second dose of SABA to recover
compared to ICS monotherapy.
To our knowledge, the effect of stepping down treat-
ment from combination therapy to ICS monotherapy on
AHR to mannitol has not yet been studied in asthmatic
adults or children. Previous studies in asthmatic adults
compared stepping down to ICS monotherapy to stepping
down to a lower dose of combination therapy.6e8 They
found a deterioration of asthma control, as measured by
peak expiratory flow, daily symptom scores and SABA use
in subjects whose LABA was withdrawn. However, the
effect on airway inflammation, asthma exacerbations,
hospitalizations and mortality was not assessed, while the
main concerns with LABA treatment focus on these
outcome measures.4 A recent study in adults compared
both step down approaches and found no significant
difference in FEV1, rescue bronchodilator use, methacho-
line PD20, sputum eosinophils, FeNO and annual rate of
severe exacerbations.5 However, recently particular
concern has risen about the risk of LABA treatment among
children. A Cochrane review comparing step up therapy
by adding a LABA to increasing the dose of ICS found that in
children combination therapy led to a trend towards an
increased risk of asthma exacerbations and hospital
admissions.3 The effect of different approaches to step
down combination therapy in children has not been
extensively studied. In a study design similar to this study
the AHR to exercise (defined as % fall in FEV1) in asthmatic
children diminished after the withdrawal of the LABA,21
suggesting an increased AHR to exercise in children on
combination therapy.
Several mechanisms could contribute to the increased
risk for asthma exacerbations and hospitalizations with
regular use of LABAs22; such as the development of bron-
chodilator tolerance, an increased AHR to allergen, inter-
action with corticosteroid receptors, masking of symptoms
and altered mucociliary clearance.23 In this study, recovery
time from bronchoconstriction after rescue therapy with
a SABA was significantly longer after long-term use of LABA/
ICS combination therapy. A prolonged recovery time after
stepping up treatment with a LABA has been described in
both adults and children after histamine,11 exercise13 and
methacholine10,14 challenges. The mechanism by which
tolerance develops is not fully unraveled, but is well known
that prolonged exposure to agonists desensitizes G-protein-
coupled receptors, such as the beta2-adenoceptor. The
principal mechanism of desensitization is cyclic-AMP-de-
pendent and -independent phosphorylation of the receptor,
which results in a limitation of receptor function. After
more prolonged exposure to an agonist, an internalization
of receptors occurs and the total transit time for the
recycling of receptors is increased, which results in a net
loss of receptors on the cell membrane (downregulation).
Eventually, there is a breakdown of receptors which can
only be replaced by synthesis of new receptors through
transcription of the beta2-receptor gene.9,24
The downregulation and desensitization of the beta2-
adrenoreceptor result in a decreased response to rescue SABA
treatment in circumstances of acute bronchoconstriction.
696 E.T.G. Kersten et al.The process of desensitization differs in different types of
cells, which may be explained by a variation in the receptor
reserve between tissues and a differential resensitization
rate. Mast cells appear to desensitize more rapidly than
smooth muscle cells.9 Therefore, tolerance might be more
profound against indirect bronchoprovocational stimuli,
such as mannitol, that act on inflammatory cells (such as
mast cells), than againstdirect stimuli, suchasmethacholine,
that act directly on airway smooth muscle cells.25
The response to mannitol in asthmatics is supposed to
mimic the airway response to exercise, as both increase the
osmolarity of the airway surface liquid, triggering mediator
release from mast cells. In a previous study by our study
group the AHR to exercise in asthmatic children decreased
after combination therapy was stepped down to ICS mon-
otherapy.21 We therefore expected a similar reduction in
AHR to mannitol, which did not occur. We speculate that
this discrepancy in results could be explained by differ-
ences in the physical responses to exercise and mannitol.
Mannitol is primarily deposited in the conducting airways,
because of its particle size,26 while exercise induced
hyperpnoea can dehydrate the peripheral airways as well.27
The amount of mast cells is greater in smaller airways,28
where only a small part of the inhaled mannitol powder
will penetrate. Therefore, a change in responsiveness in
the small airways due to desensitization of mast cells is
more likely to be detected with an exercise challenge.
Secondly, the rate of change in osmolarity, which is sug-
gested to be a determinant of AHR,29 may be important.
This rate is likely to be slower with a mannitol challenge
which is performed according to a stepwise protocol with
increasing doses. Thirdly, the fall in FEV1 after exercise is
usually greater than after mannitol, because a mannitol
challenge ends when FEV1 falls 15%. Wraight et al.
demonstrated that, in the same patient, the effect of
tolerance becomes more apparent with increasing degrees
of bronchoconstriction.30 Therefore the effect of tolerance
might have been more apparent after an exercise challenge
compared to a mannitol challenge.
Several limitations of this study need to be addressed.
Firstly, there was no control group in whom we did not
change the medication regimen, making this study suscep-
tible to bias due to an improved adherence. We measured
adherence by interviewing the children and found no
difference in reported adherence before both challenges.
Secondly, although all children used combination therapy,
they were prescribed different medication regimens and
different doses of ICSs. Five children were using leukotriene
antagonists (LTRA), which are known to shorten recovery
time following mannitol.31 We found no significant differ-
ence in recovery time for children on LTRA compared to
children not on LTRA. Thirdly, we only measured short term
effects of the withdrawal of the LABA and therefore
could not study long term outcomes, such as asthma exac-
erbations and hospitalizations.
A long recovery time and tolerance to a rescue bron-
chodilator are likely to affect children in daily life, as they
compromise their athletic performance and participation
in active play and sports with peers. Failure to respond to
rescue bronchodilators could offer a possible explanation
for the association between LABA use and asthma related
intubations and mortality. Theoretically, bronchodilatortolerance could be overcome by increasing the dose of
SABAs, which has happened in the last decades in treat-
ment of acute exacerbations. However, Haney and Hancox
found that the response to high dose nebulised salbutamol
was still 15% lower after regular formoterol compared to
placebo.32
This study shows that in short-term follow-up (one
month), stepping down clinically stable children from
LABA/ICS combination therapy to ICS monotherapy did not
change AHR to mannitol and FeNO and did not alter asthma
control as measured by spirometry, SABA use and ACT
score. The withdrawal of the LABA led to a significantly
shorter recovery time following a rescue SABA after
a mannitol challenge, suggesting a reversal of previously
developed bronchodilator tolerance. Future studies should
be directed at the longer term effects of different step
down approaches from combination therapy in asthmatic
children.
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